Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal serogroup B vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Meningococcal serogroup B vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Healthy males or females between, and including, 12 and 18 years of age at the time of the first vaccination. * Female subjects must be of non-childbearing potential. Exclusion Criteria: * Previous vaccination against or history of meningococcal B or C, or hepatitis A diseas...
Meningococcal serogroup B vaccine is an investigational vaccine being studied for the prevention of meningococcal infections. It is intended for use in healthy adolescents aged 12 to 18 years. The vaccine is currently in clinical development and has not been approved for use.
Meningococcal serogroup B vaccine is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in the target adolescent population.
Meningococcal serogroup B vaccine is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the vaccine remains under investigation for its intended use.
Meningococcal serogroup B vaccine has been studied in one completed Phase 2 clinical trial, identified as NCT00137917. This trial evaluated the immunogenicity and safety of a three-dose schedule of the vaccine in healthy adolescents aged 12 to 18 years. The trial enrolled 478 participants.
Meningococcal serogroup B vaccine is classified as a monoclonal antibody modality, although it is being developed as a vaccine. The investigational product is designed to elicit an immune response against meningococcal serogroup B bacteria, which cause meningococcal infections.